Table 1.

Clinical trials and preclinical drugs targeting ferroptosis and lipid metabolism for antitumor treatment

Nos.	Drugs	Target	Clinical use/clinical trials	Refs.
1	Sorafenib	System ${\mathrm{x}}_{\mathrm{c}}^{-}$ inhibitor	Renal cell, thyroid, and hepatocellular carcinoma treatment	135–137
2	Altretamine	GPX4 inhibitor	Ovarian cancer treatment	139,140
3	Buthionine sulfoximine	γ-GCS inhibitor	Clinical trials for neuroblastoma treatment	21,42,96
4	Statins	Block biosynthesis of CoQ10	Cholesterol reducing agents	83
5	Sulfasalazine	System ${\mathrm{x}}_{\mathrm{c}}^{-}$ inhibitor	Rheumatoid arthritis and inflammatory bowel diseases treatment/clinical trials for glioma treatment	135,138
6	Lapatinib and neratinib	Kinase inhibitor and alters iron transport system	Clinical trials for solid and metastatic breast cancer treatment	141,142
7	BAY-87-2243	Mitochondrial complex I inhibitor/HIF-1 inhibitor	Phase I trial for treatment of advanced malignancies	143
8	Salinomycin	Antioxidant properties inhibitor and alters iron transport system	Preclinical trials for breast cancer treatment	144–146
9	MF-438	SCD1 inhibitor	Preclinical trials for melanoma, breast and lung cancer treatment	41,148–150
10	CAY10566	SCD1 inhibitor	Preclinical trials for breast, prostate and liver cancer treatment	41,151–153
11	Aminooxyacetic acid	Mitochondrial fatty-acid synthesis	Preclinical trials for colon cancer treatment	4,155,156
12	Triacsin C	ACSL1,3,4 inhibitor	Preclinical trials for cancer treatment	47,157
13	thiazolidinediones	ACSL4 inhibitor	Diabetes/clinical trials for cancer treatment	10,157
14	Zileuton	5-LOX inhibitor	Clinical trials for lung, head and neck cancer and chronic myelogenous leukemia treatment	158–161
15	Baicalein	12/15-LOX inhibitor	Clinical trials for acute lymphocytic leukemia treatment	29,162